UBS Group set a €110.00 ($127.91) target price on Bayer (FRA:BAYN) in a research note released on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
Other equities analysts have also recently issued reports about the company. Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer and gave the company a buy rating in a research report on Monday. HSBC set a €63.00 ($73.26) target price on Bayer and gave the stock a neutral rating in a report on Wednesday, August 7th. Baader Bank set a €123.00 ($143.02) price target on Bayer and gave the stock a buy rating in a research note on Wednesday, October 30th. Kepler Capital Markets set a €70.00 ($81.40) price target on Bayer and gave the company a neutral rating in a report on Wednesday, October 30th. Finally, Sanford C. Bernstein set a €90.00 ($104.65) price target on Bayer and gave the company a buy rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of €80.47 ($93.57).
Shares of BAYN traded down €1.04 ($1.21) on Tuesday, hitting €69.15 ($80.41). 2,869,350 shares of the stock traded hands. The business has a 50 day simple moving average of €67.00 and a 200 day simple moving average of €61.78. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Using other technical indicators with support levels
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.